In addition to PRESENT, the biopharmaceutical company Galena Biopharma developed other two studies with NeuVax in combination with trastuzumab (Herceptin®; Genentech/Roche) for BC: a Phase IIb trial in node positive (or node negative if negative for both ER and PR) BC patients with HER2 IHC 1+/2+ (ClinicalTrials.gov identifier: NCT01570036); a Phase II trial in high-risk node positive or negative HER2 IHC 3+ patients (ClinicalTrials.gov identifier: NCT02297698). Here, ERBB2 is linked to breast cancer.